| Autor: |
A T C, Chan, V H F, Lee, R-L, Hong, M-J, Ahn, W Q, Chong, S-B, Kim, G F, Ho, P B, Caguioa, N, Ngamphaiboon, C, Ho, M A S A, Aziz, Q S, Ng, C-J, Yen, N, Soparattanapaisarn, R K-C, Ngan, S K, Kho, M L A, Tiambeng, T, Yun, V, Sriuranpong, A P, Algazi, A, Cheng, E, Massarelli, R F, Swaby, S, Saraf, J, Yuan, L L, Siu |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Annals of Oncology. 34:251-261 |
| ISSN: |
0923-7534 |
| DOI: |
10.1016/j.annonc.2022.12.007 |
| Popis: |
Pembrolizumab previously demonstrated robust antitumor activity and manageable safety in a phase Ib study of patients with heavily pretreated, PD-L1-positive, recurrent or metastatic nasopharyngeal carcinoma (NPC). The phase III KEYNOTE-122 study was conducted to further evaluate pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent and/or metastatic NPC. Final analysis results are presented.KEYNOTE-122 was an open-label, randomized study conducted at 29 sites, globally. Participants with platinum-pretreated recurrent and/or metastatic NPC were randomly assigned (1:1) to pembrolizumab or chemotherapy with capecitabine, gemcitabine, or docetaxel. Randomization was stratified by liver metastasis (present versus absent). The primary end point was overall survival (OS), analyzed in the intention-to-treat population using the stratified log-rank test (superiority threshold, one-sided P = 0.0187). Safety was assessed in the as-treated population.Between May 5, 2016, and May 28, 2018, 233 participants were randomly assigned to treatment (pembrolizumab, n = 117; chemotherapy, n = 116); Most participants (86.7%) received study treatment in the second-line or later setting. Median time from randomization to data cutoff (November 30, 2020) was 45.1 months (interquartile range, 39.0-48.8). Median OS was 17.2 months (95% confidence interval [CI], 11.7-22.9) with pembrolizumab and 15.3 months (95% CI, 10.9-18.1) with chemotherapy (hazard ratio, 0.90 [95% CI, 0.67-1.19; P = 0.2262]). Grade 3-5 treatment-related adverse events occurred in 12 of 116 participants (10.3%) with pembrolizumab and 49 of 112 participants (43.8%) with chemotherapy. Three treatment-related deaths occurred: 1 participant (0.9%) with pembrolizumab (pneumonitis) and 2 (1.8%) with chemotherapy (pneumonia, intracranial hemorrhage).Pembrolizumab did not significantly improve OS compared with chemotherapy in participants with platinum-pretreated recurrent and/or metastatic NPC but did have manageable safety and a lower incidence of treatment-related adverse events.ClinicalTrials.gov, NCT02611960. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
